Aiming to Boost Molecular Dx Portfolio, Cepheid Acquires Assay Maker Sangtec | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
In an effort to expand its emerging molecular diagnostics business, Cepheid announced last week that it has acquired Sangtec Molecular Diagnostics from Altana Pharma for approximately $27 million in cash.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.